SNMMI 2025: First-in-class antibody radioconjugate ATNM-400 exhibits potent anti-tumor activity and overcomes resistance to enzalutamide and 177Lu-PSMA-617 in prostate cancer models
ATNM-400 AACR 2025: More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models
Actimab-A AACR 2025: Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute Myeloid Leukemia
Actinium Pharmaceuticals KOL Presentation: Discussing Positive Results from the Pivotal Phase 3 SIERRA Trial of Iomab-BKOL Event with Dr. Sergio Giralt
